Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I ##STR00001##
wherein R.sup.1, R.sup.2, linker, PEG, n and o are as defined herein.

Generally spherical resin particles formed of a thermoplastic resin, having a sphericity of 0.90 to 1.00, a light scattering index of 0.5 to 1.0 and a linseed oil absorption of 30 to 150 mL/100 g.

A biodegradable based polymers for the production of biodegradable medical applications is provided. The biobased material has a copolymer constituted by dextran modified with glycidyl methacrylate and poly (#-caprolactone) modified with 2-isocyanatoethylmethacrylate, which are combined in different formulations and used to produce membranes, 3-D scaffolds and hollow tubes that can be used as biomedical devices for diverse applications such as drug delivery systems, tissue engineering scaffolds, repair and regeneration of peripheral nerves, among others.

Degradable hyperbranched epoxy resin and a preparation method thereof, wherein the preparation method comprises carrying out a reaction between a cyclotriazine compound and a carboxyl-sourced compound to prepare a carboxyl-terminated or hydroxy-terminated hyperbranched polymer; then reacting with epoxy chloropropane to obtain a degradable hyperbranched epoxy resin of which the molecular weight is about 1,900-22,000 g/mol. After the degradable hyperbranched epoxy resin is cured, a cyclotriazine structure can be completely degraded within 2 h in a phosphoric acid solution at the temperature of 80° C., thus realizing the recycle of the epoxy resin. The invention has simple process, and the product is degradable and has self-strengthening and self-toughening functions, and is expected to be used in the fields of strengthening and toughening of epoxy resins, solvent-free coatings etc.

A chemical composition for a degradable polymeric material includes an isocyanate terminated polyester prepolymer, including prepolymer units as a main chain with a plurality of isocynanates at ends of the main chain, and a cross-linking agent. The isocyanate terminated polyester prepolymer has a structural formula as follows:

ONC—R″—NH—[—CO—R—R″′-]n-NH—R″—CNO, wherein R″′ is selected from a group consisting of —O— and —CO—O—R′—O—,

##STR00001##

wherein R, R′ and R″ are an aryl group or alkyl group and wherein n is a number of prepolymer units corresponding to length of the main chain. The composition degrades at a rate and at a delay depending on temperature and the composition for a component of a downhole tool. The composition has strength and elasticity for a component of a downhole tool.

Disclosed is a composition including controlled release particles, wherein each of the controlled release particles includes: (a) a core including at least one hydrophobic active ingredient; and (b) a wall at least partially surrounding the core and including the reaction products of: (i) an organofunctional silane; (ii) an epoxy; (iii) an amine; (iv) an isocyanate; (v) an epoxide curing agent; wherein the controlled release particles are effective to retain the at least one hydrophobic active ingredient upon exposure to water and effective to release the at least one hydrophobic active ingredient in response to friction. A method for preparing the composition is also disclosed.

Disclosed is a composition including controlled release particles, wherein each of the controlled release particles includes: (a) a core including at least one hydrophobic active ingredient; and (b) a wall at least partially surrounding the core and including the reaction products of: (i) an organofunctional silane; (ii) an epoxy; (iii) an amine; (iv) an isocyanate; (v) an epoxide curing agent; wherein the controlled release particles are effective to retain the at least one hydrophobic active ingredient upon exposure to water and effective to release the at least one hydrophobic active ingredient in response to friction. A method for preparing the composition is also disclosed.

Disclosed is a composition including controlled release particles, wherein each of the controlled release particles includes: (a) a core including at least one hydrophobic active ingredient; and (b) a wall at least partially surrounding the core and including the reaction products of: (i) an organofunctional silane; (ii) an epoxy; (iii) an amine; (iv) an isocyanate; (v) an epoxide curing agent; wherein the controlled release particles are effective to retain the at least one hydrophobic active ingredient upon exposure to water and effective to release the at least one hydrophobic active ingredient in response to friction. A method for preparing the composition is also disclosed.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.